Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  enzalutamide
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Cardiovascular complications during the treatment of castration-resistant prostate cancer with the use of modern antiandrogens: abiraterone acetate and enzalutamide

100%
Grabysa R., Chmielewska A.
OncoReview
|
2021
|
vol. 11
|
issue 3
61-67
EN
Modern antiandrogens: abiraterone acetate (inhibitor of CYP17 cytochrome) and enzalutamide (irreversible inhibitor of androgen receptor) are the drugs that are increasingly often administered in treatment of castration-resistant prostate cancer. Despite their clinical efficacy, especially in terms of prolonged survival and improved quality of life of patients, they pose of problem for a practicing oncologist such as possible cardiovascular complications (particularly arterial hypertension), which may lead to the cessation of this form of therapy. This article provides a brief overview of the mechanisms responsible for the above complications, including practical recommendations in the event such complications arise. A simple scheme of action for control of cardiovascular risk factors has been presented, which can improve the prognosis in this population of patients.
2
Publication available in full text mode
Content available

The role of enzalutamide in the treatment of prostate cancer from the perspective of Polish oncologists

88%
Bal W., Gajda M.
OncoReview
|
2022
|
vol. 12
|
issue 2
45-49
EN
For several years, prostate cancer has remained the most common malignancy in male patients in Poland. A large number of patients combined with rising costs of therapy translate into a significant socio-economic burden. In a clinical oncologist’s practice, we usually deal with patients with advanced prostate cancer. Taking into account the poorer prognosis in advanced disease, development of new therapeutic options as well we their adequate selection is of paramount importance. Enzalutamide is one of the second-generation androgen axis inhibitors, which has the ability to overcome resistance to androgen deprivation therapy by inhibiting the androgen-DNA signalling on several levels. Its efficacy and safety had been proven in numerous phase II and phase III clinical studies and it has been registered by regulatory authorities in the United States and European Union in the treatment of mCRPC, mCSPC and nmCRPC. In this article selected issues related to the treatment of prostate cancer are discussed, with particular emphasis on the role of enzalutamide (including its mechanism of action, indications, efficacy and safety).
3
Publication available in full text mode
Content available

Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study

75%
Sikora-Kupis B.
OncoReview
|
2023
|
vol. 13
|
issue 1
6-8
EN
A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.